
AARD Stock Forecast & Price Target
AARD Analyst Ratings
Bulls say
Aardvark Therapeutics is currently experiencing a delay in their Phase 3 HERO trial due to reversible cardiac observations found during safety monitoring in a healthy volunteer study. While the impact on the trial timeline is uncertain, if the company receives clearance to resume patient dosing in May and completes enrollment by 4Q26, data could be reported in early 2027. Therefore, we are cautiously downgrading our rating to Neutral and suspending our price target until more information is available.
Bears say
Aardvark Therapeutics is facing several significant challenges, including a full clinical hold placed by the FDA on its lead product ARD-101, uncertainty surrounding data from the discontinued HERO trial, and a lack of clear timelines for future developments. Additionally, the company's cash runway only extends to mid-2027 per management's guidance, posing a potential risk for investors. Without more clarity on the company's near-term outlook, it may be best to wait on the sidelines before considering an investment in Aardvark.
This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AARD Analyst Forecast & Price Prediction
Start investing in AARD
Order type
Buy in
Order amount
Est. shares
0 shares